PluroGen Therapeutics, Inc. to Attend European Wound Management Association (EWMA) Conference 23-25 May in Vienna, AU

Posted on February 19, 2015 by - Uncategorized

Download PDF

Norristown, PA, 14 May, 2012

PluroGen Therapeutics, Inc, an emerging leader in advanced wound care solutions, announced today that it will be attending the European Wound Management Association (EWMA) conference to be held at the Austria Center in Vienna on 23-25 May, 2012. PluroGen will be discussing and demonstrating its PluroGel® line of wound care products, recent strategic developments and product pipeline. Neal Koller, President and CEO of PluroGen and Kati Weiss, PluroGen Europe, will be available throughout the conference for one-on-one meetings at the PluroGen Booth #37a, located in the conference center. To set up a meeting during the show with a PluroGen representative please email Europe@plurogen.com.

PluroGen has developed a portfolio of 3 synergistic and complementary patented technologies, including PluroGel® technologies, which are sharply focused on the burn and non-healing wounds (including chronic wound) market. PluroGel PSSD®, one of PluroGen’s line of patented Gel-based products is being used in burn and wound centers across Europe. “Our team is very excited about attending the EWMA show. There is no better forum than this to meet the people who really make a difference for patients in wound care” said Neal Koller, President and CEO of PluroGen. “We want to tell our story about how PluroGel® technology can help physicians make great strides in their day to day wound care challenges.”

About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. provides technically advanced wound and skin care products. PluroGen’s University developed products are simple yet advanced to support complex wounds to benefit patients, with an added advantage for the delicate needs of burn and wound patients in the $7B worldwide wound care market. PluroGen offers healthcare providers new, unique and cost-effective wound care tools. A key initiative for PluroGen is bringing the unique patented PluroGel® product line to doctors, nurses and patients in Europe to provide the best options in wound care to help patients have a better quality of life. PluroGen‘s headquarters and operations facility is in Norristown, PA USA, with sales and marketing offices in Europe. More information can be found on the company’s website: www.plurogen.com.

About European Wound Management Association

The European Wound Management Association (EWMA) was founded in 1991, and the association works to promote the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. Over 2000 experts, practitioners and company representatives working with wound healing and wound management will be in attendance. Additional information on the conference can be found at http://www.ewma2012.org.

Safe Harbor Statement:

The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company’s actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

VAAN MAKES SECOND INVESTMENT IN PLUROGEN

Posted on February 19, 2015 by - Uncategorized

Download PDF

FOR IMMEDIATE RELEASE Contact: Neal G. Koller

President & CEO

(Charlottesville, VA, February 11, 2010) – PluroGen Therapeutics, Inc. today announced that VAAN (the Virginia Active Angel Network) made their second investment in PluroGen.

Commenting on the VAAN’s second investment, Neal G. Koller, President & CEO of PluroGen, said, “This second VAAN investment in PluroGen represents a significant validation and confirmation of our progress and the value Plurogen provides as an investment vehicle. We are pleased VAAN’s exhaustive due diligence process resulted in their decision to invest. They have and will continue to be an appreciated active investor and help to the company.”

VAAN released today the following statement on their second investment in PluroGen:

“Virginia Active Angel Network, LLC has completed its portion of a $1.0 M Series A Preferred round today in Plurogen Therapeutics, Inc., a novel skin care & wound healing company w/ gel technologies.

VAAN invested an additional round in its portfolio company, Plurogen Therapeutics, Inc., a UVA-patented company. VAAN conducted a top-to-bottom full due diligence on PTI as the original investment was made two years ago. In Q3, 2009, PTI has 2 successful in-human use trials for its PluroGel® with Silver Sulfadiazine in Europe, became post-revenue, and received another NIH grant for $100K to study its PluroGel gel technology, including its Chitosan gel technology along with other technologies in the spray application of fat-derived stem cells for wound healing. VAAN’s original investment was a convertible note which auto-converted, and therefore this is a Series A round that matches that conversion price. Feb. 11, 2009,www.plurogen.com. Contact Neal Koller if you have an interest in this round, or the next at nkoller@plurogen.com.
Contact Letitia Green if you have an interest sufficient to need the due diligence report. Over 20 physicians are invested in this project separate from VAAN.”

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound and skin care company commercializing our multiple patent-protected technology platforms, the 1st of which is our core gel technology that provides superior and differentiated physical, bio-impact and multi-function benefits. Our multiple technology platforms are configurable to deliver a wide variety of medicinal and beneficial compounds as protected and advanced therapeutic and topical products for simple and complex skin care and burn and wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).

PluroGen’s first gels, PluroGel® and ActiviGel™, are being used initially in skin and wound cleansing products, for personal skin care products and for two branded topical antimicrobial products, PluroGel® Barrier Gels and PluroGel® Barrier Dressings. PluroGel® / ActiviGel™ technology is currently in routine use at the University of Virginia Medical Center, having shown superior results on more than 2,000 patients in two different patient populations, severe burns and chronic wounds. The PluroGen management and operational teams, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.

For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com